Bevacizumab-awwb
Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Bevacizumab-awwb |
| Trade Name | Mvasi |
| Synonyms | ABP 215 |
| Drug Descriptions |
Mvasi (bevacizumab-awwb) is a biosimilar to the anti-VEGF antibody Avastin (bevacizumab), which binds to and inhibits VEGF, resulting in decreased tumor growth and angiogenesis (PMID: 29743182). Mvasi (bevacizumab-awwb) is FDA approved for use in combination with chemotherapy in colorectal cancer, in combination with carboplatin and paclitaxel in non-squamous non-small cell lung cancer, in glioblastoma, in combination with interferon-alfa in renal cell carcinoma, and in combination with paclitaxel and cisplatin or topotecan in cervical cancer (FDA.gov). |
| DrugClasses | VEGF Antibody 15 |
| CAS Registry Number | NA |
| NCIT ID | NA |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
CKB BOOST